Fri, Jul 25, 2014, 7:34 AM EDT - U.S. Markets open in 1 hr 56 mins

Recent

% | $
Click the to save as a favorite.

Nektar Therapeutics (NKTR) Message Board

  • carylindsay1443@sbcglobal.net carylindsay1443 Oct 25, 2013 7:22 PM Flag

    FDA SPEAKING OUT OF BOTH SIDES OF THEIR MOUTH

    The FDA issues restrictions yesterday to curtail opioid abuse and turn around today and approve a more powerful opioid. But then this should give NKTR a lock on getting their drug approved.
    The Food and Drug Administration has approved a stronger, single-ingredient version hydrocodone, the widely-abused prescription painkiller.

    The agency said Friday it approved the extended-release pill Zohydro ER for patients with pain that requires "daily, around-the-clock, long-term treatment" that cannot be treated with other drugs.

    Hydrocodone is currently sold in combination pills like Vicodin to treat pain from injuries, surgery, arthritis and migraines. The new drug from Zogenix is the first pure hydrocodone drug approved in the U.S.

    The approval came as a surprise since the agency's own panel of outside advisers gave the drug an overwhelmingly negative review last year. The panel of pain specialists voted 11-2, with one abstention, against approving the drug, questioning the need for a new form of one of most widely-abused prescription drugs in U.S.

    Zohydro's approval was quickly criticized by patient safety advocates who had urged the FDA to reject the drug at the public panel last December.

    "We're just going to kill more kids and then the FDA is going to come back and say, 'oh, we made a mistake,'" said Avi Israel of Buffalo, N.Y. Israel's son Michael committed suicide in 2011 while struggling with painkiller addiction. Israel is the founder of a group called, Save the Michaels of the World, which aims to combat painkiller abuse in young people.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Removal of Acetaminophen is their differentiator. FDA is VERY aware of, and concerned about, the issues related to Acetaminophen. The 11-2 panel vote was an example of logic losing to politics. Powers that be understand there is true BENEFIT (less harm) for many patients. Hydrocodone is on the market, and presently needs to be, until we get 181. This version/option just makes it less damaging for many.

      "Zohydro ER is the first extended-release formulation hydrocodone therapy without acetaminophen. The use of products containing acetaminophen in high doses over long periods of time has the potential for causing liver injury."

      • 1 Reply to networthdev
      • "Nearly two out of every three acetaminophen overdoses are attributed to hydrocodone-acetaminophen products."

        “A significant proportion of patients on existing forms of immediate-release hydrocodone-acetaminophen combination treatments have liver disease or risk factors, and the availability of an acetaminophen-free formulation encompassing a range of hydrocodone doses is an important therapeutic option for these patients.”

    • Here what they did vs. Nektar ,,,,
      A randomized Phase 3, placebo-controlled multi-center study to evaluate the safety, efficacy and tolerability of Hydrocodone Bitartrate controlled-release capsules in subjects with chronic low back pain. Subjects will go through an open-label conversion and titration phase followed by a randomized double-blind treatment phase of HC-CR vs. Placebo. The trial will consist of a Screening Phase (up to 14 days), an open-label Conversion and Titration Phase (up to 6 weeks), a 12-week placebo-controlled Treatment Phase, and a 2-week Follow-Up Phone Call

 
NKTR
11.01+0.01(+0.09%)Jul 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.